ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1335

Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register

Dominic Seet1, Li Wearn Koh2, Preeti Dhanasekaran3, Man Hua Aw4, Rosa Lim Mui San2, Siaw Ing Yeo4 and Manjari Lahiri1, 1National University Hospital, Singapore, Singapore, 2Tan Tock Seng Hospital, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore, 4Singapore General Hospital, Singapore, Singapore

Meeting: ACR Convergence 2020

Keywords: Biologicals, Health Assessment Questionnaire (HAQ), prognostic factors, registry, Smoking

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To describe the demographic and clinical characteristics of patients with inflammatory arthritis (IA) initiating biologic disease modifying anti-rheumatic drugs (bDMARD) who use complementary and alternative medicine (CAM), and determine the impact of CAM on predicting residual functional disability at six months, as measured by the modified Health Assessment Questionnaire (mHAQ).

Methods: A prospective inception cohort study of all patients ≥ 21 years old initiating a bDMARD for IA after July 2016 was conducted in three public-sector hospitals in Singapore. Baseline and follow-up data were obtained via face-to-face or telephonic questionnaires and abstraction from medical records. Baseline characteristics were compared using chi-square test for categorical variables; and t-test and Wilcoxon signed-rank test for continuous variables in gaussian and non-gaussian distributions respectively. CAM as a predictor of mHAQ ≥ 1 at six months after starting a bDMARD was analysed using multivariate logistic regression, adjusting for other baseline characteristics. Further, interaction of CAM use and smoking was tested.

Results: 299 patients (36.2% males, 70.4% Chinese) of mean (SD) age 49.0 (13.4) years were recruited. 45.8% had rheumatoid arthritis with a mean (SD) Disease Activity Score in 28-joints (DAS-28) of 4.6 (1.2). 54.2% had a spondyloarthropathy with a mean (SD) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of 4.7 (2.2). The median (IQR) disease duration was 12.7 (4.7, 38.5) months, with a median (IQR) mHAQ of 0.4 (0.1, 0.9). 93 patients were current or prior CAM users, most commonly acupuncture (64.5%), powder (46.2%), tablets (36.6%), herbs (33.3%), suction (19.4%). Compared to non-users, CAM users had a lower mean body mass index (24.5 vs 26.8kg/m2, p=0.002), were less likely to be English-speaking (65.5% vs 85.8%, p< 0.001), more likely to be smokers (28.0% vs 16.7%, p=0.02) and to drink alcohol (33.7% vs 19.6%, p=0.009), and less likely to have cardiovascular disease (2.2% vs 8.8%, p=0.04) (Table 1). Of the 223 patients with 6-month follow-up data, 27.4% were no longer on their index bDMARD. mHAQ was available for 206 patients, median (IQR) 0.1 (0, 0.5), 12.1% with mHAQ ≥ 1. There was no association of CAM use with high mHAQ and no interaction with smoking. Advanced age (odds ratio [OR] < 0.001 [95% CI 5.3E-10 – 0.34]), smoking (OR 938.9 [95% CI 3.20 – 275884.1]), baseline mHAQ (OR 252.2 [95% CI 5.34 – 11899.2]) and Charlson’s Co-morbidity Index (CCI) score of ≥ 4 (OR 237.4 [95% CI 1.22 – 46184.4]) were independent predictors of high mHAQ (Table 2).

Conclusion: CAM use was not associated with high mHAQ at 6 months. Association with advanced age may be attributable to a tendency for elderly patients to under-report scores. Smoking was an independent predictor of residual functional disability at 6 months, even after adjusting for age, comorbidity and baseline mHAQ. More emphasis on smoking cessation may be useful to improve long-term functional outcomes in IA patients on bDMARDs.

* Missing data have been omitted from % calculations. Plus-minus values are means ± standard deviation (SD). + P-values are for differences between CAM users and non-users and were calculated by chi-square test for categorical variables, and by t-test for normally distributed continuous variables and Wilcoxon signed-rank test for non-normally distributed continuous variables. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CAM, complementary and alternative medicine; CCI, Charlson’s Co-morbidity Index; DAS-28, Disease Activity Score in 28 joints; IQR, interquartile range; mHAQ, modified Health Assessment Questionnaire; TNFi, tumour necrosis factor inhibitor.

Variables were included in the multivariable model if they were significant at P ≤ 0.2 on univariate analysis. † Not included in the multivariable model due to collinearity with mHAQ. ‡ Hypertension and hyperlipidemia were statistically significant in the univariate analysis as well, but not included in the multivariate model due to collinearity with CCI. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CAM, complementary and alternative medicine; CCI, Charlson’s Co-morbidity Index; DAS-28, Disease Activity Score in 28 joints; mHAQ, modified Health Assessment Questionnaire; TNFi, tumour necrosis factor inhibitor.


Disclosure: D. Seet, None; L. Koh, DKSH, 9, Astellas Pharma, 8; P. Dhanasekaran, None; M. Aw, None; R. Lim Mui San, None; S. Yeo, DKSH, 9; M. Lahiri, Pfizer, 5, 8, Gilead, 5, Sanofi, 9.

To cite this abstract in AMA style:

Seet D, Koh L, Dhanasekaran P, Aw M, Lim Mui San R, Yeo S, Lahiri M. Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/smoking-but-not-use-of-complementary-and-alternative-medicine-predicts-residual-functional-disability-in-patients-with-inflammatory-arthritis-on-biologic-disease-modifying-anti-rheumatic-drugs-resul/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/smoking-but-not-use-of-complementary-and-alternative-medicine-predicts-residual-functional-disability-in-patients-with-inflammatory-arthritis-on-biologic-disease-modifying-anti-rheumatic-drugs-resul/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology